



(51) International Patent Classification:

C07K 16/28 (2006.01) C07K 14/705 (2006.01)
A61K 39/395 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/US2022/028520

(22) International Filing Date:

10 May 2022 (10.05.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/187,371 11 May 2021 (11.05.2021) US

(71) Applicant: **ALPHA-5 INTEGRIN, LLC** [US/US]; 458
Carlton Court, South San Francisco, CA 94080 (US).

(72) Inventor: **RYNER, Lisa**; 458 Carlton Court, South San
Francisco, CA 94080 (US).

(74) Agent: **LIANG, Bing** et al.; Jones Day, 250 Vesey Street,
New York, NY 10281-1047 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,

CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(54) Title: ALPHA 5 BETA 1 INTEGRIN BINDING AGENTS AND USES THEREOF




FIG. 1

(57) Abstract: The present disclosure provides $\alpha 5 \beta 1$ integrin binding agents (e.g., antibodies, including multispecific antibodies, such as bispecific antibodies) and uses thereof.

[Continued on next page]

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*